Literature DB >> 26607877

Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization.

Yanni F Yu1, Dendy S Macaulay2, William M Reichmann3, Eric Q Wu4, Steven D Nathan5.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) may be complicated by episodes of acute exacerbation. This study quantified the association between occurrence of suspected acute exacerbations of IPF (AEx-IPF) in the 6 months post-IPF diagnosis with clinical outcomes and IPF-related healthcare resource utilization (HRU).
METHODS: U.S. pulmonologists participated in a retrospective chart review of IPF patients. Patient eligibility criteria included: 1) ≥40 years of age and a confirmed date of first IPF diagnosis with HRCT and/or lung biopsy between January 2011-June 2013; 2) 2 separate FVC results recorded around first diagnosis and 6 months post-diagnosis. Patients with a suspected AEx-IPF within 6 months post-diagnosis were categorized as "early AEx-IPF." Subsequent clinical outcomes and IPF-related HRU were assessed from 6 months post-diagnosis until the latest physician contact date.
RESULTS: The sample included 490 IPF patients from 168 pulmonologists; 72 (15%) patients had a suspected early AEx-IPF. At IPF diagnosis, the mean (SD) age was 61 (11) years, 68% were male, and the mean FVC percent predicted was 60% (26%). Compared to patients without a suspected early AEx-IPF, patients with an early AEx-IPF had higher mortality risk (HR = 2.87, p < 0.001) and higher rates of subsequent suspected AEx-IPF (IRR = 3.87, p < 0.001), outpatient visits (IRR = 1.46, p < 0.001), ER visits (IRR = 4.39, p < 0.001), hospitalizations (IRR = 7.96, p < 0.001), and ICU stays (IRR = 9.74, p < 0.001).
CONCLUSIONS: Using a large sample of IPF patients from varied practice settings, we found a strong relationship between suspected early AEx-IPF and worse subsequent clinical outcomes and increased IPF-related HRU. This relationship was particularly pronounced for acute resource use.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Acute exacerbations; FVC; Healthcare resource use; Idiopathic pulmonary fibrosis; Lung function; Mortality

Mesh:

Year:  2015        PMID: 26607877     DOI: 10.1016/j.rmed.2015.11.001

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  5 in total

1.  Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium.

Authors:  C Rinciog; A Diamantopoulos; A Gentilini; B Bondue; C Dahlqvist; A Froidure; W A Wuyts; S Soulard
Journal:  Pharmacoecon Open       Date:  2020-09

2.  Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.

Authors:  Brett Ley; Jeffrey Swigris; Bann-Mo Day; John L Stauffer; Karina Raimundo; Willis Chou; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2017-09-15       Impact factor: 21.405

3.  Acute exacerbation of idiopathic pulmonary fibrosis: who to treat, how to treat.

Authors:  Tejaswini Kulkarni; Steven R Duncan
Journal:  Curr Pulmonol Rep       Date:  2019-11-26

4.  The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.

Authors:  Alex Diamantopoulos; Emily Wright; Katerina Vlahopoulou; Laura Cornic; Nils Schoof; Toby M Maher
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

5.  Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.

Authors:  Mitra Corral; Kathryn DeYoung; Amanda M Kong
Journal:  BMC Pulm Med       Date:  2020-07-11       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.